When might CSL shares hit the $300-mark again?

CSL is on track for $300, if one broker is to be believed.

| More on:
Five arrows hit the bullseye of five round targets lined up in a row, with a blue sky in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Last month, I discussed the prospects of the CSL Limited (ASX: CSL) share price reaching $300 before Christmas. Back then, on 17 November, CSL shares were going for $258.21. Today, those same shares are asking $266.02 at the time of writing, so we've made some progress.

But, CSL has just over three weeks to get to that magic $300 mark – in what would be a rise of almost 13%. I said it then, and I'll say it again now, I doubt this will happen, although stranger things have happened.

So if CSL is not destined to be a $300 share by Christmas, when will it be?

The milestone $300 would not be new territory for this ASX 200 healthcare stock. CSL shares first clocked $300 back in early 2020. By February of that year, the company had hit its still-reigning all-time high of just over $340 a share.

But it hasn't reached those kinds of heights since. So perhaps the stock is primed for a breakout.

Is the CSL share price getting to $300 anytime soon?

Well, making share price predictions for any ASX share is a fraught exercise. After all, a large part of what determines a company's share price is the earnings multiple investors are willing to pay for it at any given moment. CSL has traded relatively rich for a long time.

Earlier this year, the company had a price-to-earnings (P/E) ratio of over 45. But today, thanks in large part to a healthy bump in earnings in 2023, that P/E ratio has come down to 38.7 at present.

If investors wanted to push it back up over 45, then we could well see CSL shares with a '3' in front of them soon.

If you ask me, I would say that the best shot for CSL to get back over $300 will be its next earnings report. The company is next due to report to investors on 14 February next year. Say CSL can pull a Valentine's Day gift out of its hat by showing it can successfully navigate a potentially rising Australian dollar. That might be its best shot at $300 for the next little while.

Remember, CSL reports its earnings in US dollars, but its shares are priced in the local currency. Thus, if the Aussie dollar appreciates in value against the greenback, we could see its earnings (and dividends) fall in Australian dollar terms.

Saying that, my Fool colleague Bernd reported just yesterday that a strategist at ASX broker Citi has named CSL as one of the most likely beneficiaries of a rising Aussie dollar.

ASX broker calls a $334 price

But let's take a look at what another broker is saying about CSL's share price trajectory.

As we also discussed yesterday, ASX broker Morgan Stanley has just retained its buy rating on the CSL share price. Morgan Stanley has a 12-month sharp price target of $334 on CSL right now. That's thanks to expected growth in the company's plasma volumes.

So if this broker is to be believed, CSL will comfortably be back over $300 by this time next year. Let's see if that does indeed come to pass.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is this ASX 200 pharmaceuticals stock crashing 15% today?

Investors haven't responded positively to a sales update.

Read more »

A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.
Share Gainers

This small-cap ASX stock just rocketed 39%. What's doing?

A stock no one has heard of is lighting up trading screens on Wednesday. You might hear this name more…

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Has the CSL share price got further to fall?

ASX experts weigh in on what's next for CSL.

Read more »

Shot of a young scientist using a laptop while conducting research in a laboratory.
Healthcare Shares

2 popular ASX 200 healthcare shares tanking on earnings updates

Let's check out the earnings reports from these two ASX 200 healthcare shares today.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Hoping to bag the record Medibank dividend? Here's what you need to do

Time is running out if you'd like to bank the ASX 200 healthcare stock's largest-ever dividend.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Earnings Results

Nanosonics share price crashes 14% on first-half profit crunch

Investors haven't responded positively to the release of the company's half-year results.

Read more »

Three excited business people cheer around a laptop in the office
Healthcare Shares

Here's why ResMed shares can jump a further 20%

Investors have done very well from this stock recently. The good news is that analysts expect the trend to continue.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Share Gainers

If you'd put $20,000 in this ASX healthcare stock during COVID-19, you'd have $257,000 now

You could have become filthy rich in just 4 years. Just think about that.

Read more »